Preclinical and first-in-human evaluation of 18F-labeled D-peptide antagonist for PD-L1 status imaging with PET

[1]  Jamie B. Spangler,et al.  Pharmacodynamic measures within tumors expose differential activity of PD(L)-1 antibody therapeutics , 2021, Proceedings of the National Academy of Sciences.

[2]  G. Hospers,et al.  18F-BMS986192 PET Imaging of PD-L1 in Metastatic Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors: A Pilot Study , 2021, The Journal of Nuclear Medicine.

[3]  R. Boellaard,et al.  PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non–Small Cell Lung Cancer , 2021, The Journal of Nuclear Medicine.

[4]  M. Pomper,et al.  First-in-Humans Evaluation of a PD-L1–Binding Peptide PET Radiotracer in Non–Small Cell Lung Cancer Patients , 2021, The Journal of Nuclear Medicine.

[5]  R. Boellaard,et al.  Study of 89Zr-Pembrolizumab PET/CT in Patients With Advanced-Stage Non–Small Cell Lung Cancer , 2021, The Journal of Nuclear Medicine.

[6]  Nan Li,et al.  Clinical translational evaluation of Al18F-NOTA-FAPI for fibroblast activation protein-targeted tumour imaging , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  Yakun Wan,et al.  Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy , 2020, Journal for ImmunoTherapy of Cancer.

[8]  Kyung-Han Lee,et al.  89Zr-Labeled Anti-PD-L1 Antibody PET Monitors Gemcitabine Therapy-Induced Modulation of Tumor PD-L1 Expression , 2020, The Journal of Nuclear Medicine.

[9]  L. Zitvogel,et al.  Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors , 2020, Nature Reviews Clinical Oncology.

[10]  E. Calvo,et al.  Clinical Challenges of Immune Checkpoint Inhibitors. , 2020, Cancer cell.

[11]  S. de Jong,et al.  Molecular Imaging of PD-L1 Expression and Dynamics with the Adnectin-Based PET Tracer 18F-BMS-986192 , 2020, The Journal of Nuclear Medicine.

[12]  Zachary T. Rosenkrans,et al.  ImmunoPET: Concept, Design, and Applications. , 2020, Chemical reviews.

[13]  R. Boellaard,et al.  Quantification of PD-L1 Expression with 18F-BMS-986192 PET/CT in Patients with Advanced-Stage Non–Small Cell Lung Cancer , 2020, The Journal of Nuclear Medicine.

[14]  M. Atkins,et al.  Checkpoint inhibitor immunotherapy in kidney cancer , 2020, Nature Reviews Urology.

[15]  G. Feldmann,et al.  Immune Checkpoint Imaging in Oncology: A Game Changer Toward Personalized Immunotherapy? , 2020, The Journal of Nuclear Medicine.

[16]  P. Sharma,et al.  Dissecting the mechanisms of immune checkpoint therapy , 2020, Nature Reviews Immunology.

[17]  E. D. de Vries,et al.  Molecular imaging biomarkers for immune checkpoint inhibitor therapy , 2020, Theranostics.

[18]  L. Qiu,et al.  PET Imaging of Tumor PD-L1 Expression with a Highly Specific Nonblocking Single-Domain Antibody , 2020, The Journal of Nuclear Medicine.

[19]  C. H. Nielsen,et al.  Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  Lingzhou Zhao,et al.  Early Phase I Study of a 99mTc-Labeled Anti–Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non–Small Cell Lung Cancer , 2019, The Journal of Nuclear Medicine.

[21]  Ronald Boellaard,et al.  89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer , 2018, Nature Medicine.

[22]  M. Pomper,et al.  Peptide-Based 68Ga-PET Radiotracer for Imaging PD-L1 Expression in Cancer , 2018, Molecular pharmaceutics.

[23]  Martin C. Wright,et al.  Synthesis and Biologic Evaluation of a Novel 18F-Labeled Adnectin as a PET Radioligand for Imaging PD-L1 Expression , 2017, The Journal of Nuclear Medicine.

[24]  J. Taube,et al.  Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy , 2016, Nature Reviews Cancer.

[25]  D. Scott,et al.  Small molecules, big targets: drug discovery faces the protein–protein interaction challenge , 2016, Nature Reviews Drug Discovery.

[26]  Lei Liu,et al.  Blocking of the PD-1/PD-L1 Interaction by a D-Peptide Antagonist for Cancer Immunotherapy. , 2015, Angewandte Chemie.

[27]  P. Sharma,et al.  The future of immune checkpoint therapy , 2015, Science.

[28]  Lorenz M. Mayr,et al.  Identification of d-Peptide Ligands Through Mirror-Image Phage Display , 1996, Science.

[29]  P. Mischel,et al.  Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma , 2007, Nature Medicine.